Parathyroid Hormone (1-34) (human) (trifluoroacetate salt) (Synonyms: LY333334, PTH (1-34)) |
| Katalog-Nr.GC44567 |
Parathyroid hormone (PTH) (1-34) is an N-terminal fragment of PTH that regulates bone remodeling.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Parathyroid hormone (PTH) (1-34) is an N-terminal fragment of PTH that regulates bone remodeling. It is a PTH receptor agonist that binds to the PTH1 receptor (IC50 = 2 nM) and increases cAMP accumulation (IC50 = 0.22 pM) in HEK293 cells expressing human PTH1. PTH (1-34) also stimulates cAMP accumulation in Saos-2 human osteoblast-like cells (IC50 = 0.38 nM) and bone resorption from neonatal mouse calvariae in vitro. In vivo, PTH (1-34) (40 µg/kg per day) increases bone mass in an ovariectomized adult rat model of postmenopausal osteoporosis. It also increases proteoglycan content and inhibits articular cartilage degeneration in knee joints in a mouse model of injury-induced osteoarthritis when administered at a dose of 40 µg/kg per day immediately following injury. Formulations containing PTH (1-34) have been used in the treatment of osteoporosis in men and postmenopausal women who are at high risk for fracture.
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *